CUTISS wins Top 100 Swiss Startup Award 2020

Zurich, Switzerland, September 10, 2020 – CUTISS AG, an innovative Swiss Life Science Company aiming to provide patients that suffer from large and deep skin defects with an automatically produced, personalized skin tissue therapy, denovoSkin™, today announced it has won the Top 100 Swiss Startup Award 2020, granted by a jury of 100 leading startup experts and investors within the framework of an award ceremony yesterday evening in Zurich. In 2019, CUTISS achieved rank six out of 100 and in 2018, the Company reached rank five out of 100.

The win of this leading Swiss Startup award is reflecting the significant progress CUTISS achieved in the last twelve months: Despite the Covid-19 pandemic, the Company continued its activities, onboarded additional study centers and closed an oversubscribed Series B financing round, raising funds of more than CHF 20 Million. In addition, in August CUTISS received a positive opinion from the Paediatric Committee of the European Medicines Agency on the Company’s proposed Paediatric Investigation Plan for denovoSkin™ and significantly advanced its automation program. Most recently, staff members moved into a new office at the Biotechnopark in Schlieren (Zurich), next to the Company’s production and R&D facilities. CUTISS currently employs 28 employees, of which eight joined the Company since September 2019.

About the Top 100 Swiss Startup Award
The TOP 100 Swiss Startup Award has become a benchmark in Switzerland’s startup ecosystem: In the last 10 years, the event has featured 397 startups that have created more than 8’700 jobs and raised CHF 4.2 billion. Forty-two exits and two IPOs top off the achievements so far. Each year since 2011, the 100 most innovative and promising Swiss startups are picked by a jury of 100 leading investors and startup experts. www.top100startups.swiss/

About CUTISS AG
CUTISS is a Swiss Life Science Company, spin-off of the University of Zurich, developing personalized skin graft technologies for the treatment of a large spectrum of skin defects. Its lead product candidate, denovoSkin™, has been tested in a phase I clinical trial on pediatric patients at the University Children’s Hospital in Zurich; denovoSkin™ was well tolerated by all patients with no safety issue reported. Phase II studies are currently ongoing in Switzerland and the European Union and are partially funded by Wyss Zurich. denovoSkin™ has received Orphan Drug Designation for the treatment of burns by Swissmedic, EMA and FDA. In addition, denovoSkin™ aims to improve life quality of elective (reconstructive treatments) patients as well and it can further be developed in terms of complexity by adding pigmentation. www.cutiss.swiss

Contact
CUTISS AG, CEO Dr. Daniela Marino, +41 44 244 36 60, info@cutiss.swiss

Scroll to Top

Newsletter

Would you like to contact us as a journalist?

This website uses cookies to ensure you get the best experience on our website.